Adar Poonawalla says hopes to launch Covovax trials in India by September 2021
In August 2020, American vaccine company Novavax had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373
Poonawalla said that the company has chosen only certain technologies which would be easier to scale up and at the same time cut down the production time. He further said that the company has taken a lot of risk and planned the execution in early 2020.
New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on March 27 said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, American vaccine company Novavax had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate for low and middle-income countries and India.
“Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!,” Poonawalla said in a tweet.
Published: March 27, 2021, 15:01 IST